These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37460275)

  • 1. Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study.
    Mensch N; Hemmig AK; Aschwanden M; Imfeld S; Stegert M; Recher M; Staub D; Kyburz D; Berger CT; Daikeler T
    RMD Open; 2023 Jul; 9(3):. PubMed ID: 37460275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal Study.
    Hocevar A; Rotar Z; Jese R; Semrl SS; Pizem J; Hawlina M; Tomsic M
    Medicine (Baltimore); 2016 Apr; 95(14):e3210. PubMed ID: 27057850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study.
    Felten L; Leuchten N; Aringer M
    Rheumatology (Oxford); 2022 May; 61(5):1997-2005. PubMed ID: 34487149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study.
    Muratore F; Marvisi C; Castrignanò P; Croci S; Bonacini M; Boiardi L; Ricordi C; Galli E; Besutti G; Spaggiari L; Versari A; Giorgi Rossi P; Pipitone N; Salvarani C
    Semin Arthritis Rheum; 2024 Feb; 64():152351. PubMed ID: 38142617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.
    Kermani TA; Warrington KJ; Cuthbertson D; Carette S; Hoffman GS; Khalidi NA; Koening CL; Langford CA; Maksimowicz-McKinnon K; McAlear CA; Monach PA; Seo P; Merkel PA; Ytterberg SR;
    J Rheumatol; 2015 Jul; 42(7):1213-7. PubMed ID: 25877501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
    Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
    JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does leflunomide have a role in giant cell arteritis? An open-label study.
    Hočevar A; Ješe R; Rotar Ž; Tomšič M
    Clin Rheumatol; 2019 Feb; 38(2):291-296. PubMed ID: 30084049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis.
    Ma J; Khalidi N; Wierzbicki O; Alqutami A; Ioannidis G; Pagnoux C
    Int J Rheum Dis; 2020 Aug; 23(9):1233-1239. PubMed ID: 32776676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and predictors of relapse in giant cell arteritis: A systematic review and meta-analysis.
    Moreel L; Betrains A; Molenberghs G; Vanderschueren S; Blockmans D
    Joint Bone Spine; 2023 Jan; 90(1):105494. PubMed ID: 36410684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Relapses or Recurrences in Patients With Giant Cell Arteritis: A Medical Records Review Study.
    Gomes de Pinho Q; Daumas A; Benyamine A; Bertolino J; Ebbo M; Schleinitz N; Harlé JR; Jarrot PA; Kaplanski G; Berbis J; Boucekine M; Rossi P; Granel B
    J Clin Rheumatol; 2023 Jun; 29(4):e25-e31. PubMed ID: 36727749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Diabetes Mellitus among Patients Diagnosed with Giant Cell Arteritis or Granulomatosis with Polyangiitis: Comparison with the General Population.
    Faurschou M; Ahlström MG; Lindhardsen J; Obel N; Baslund B
    J Rheumatol; 2017 Jan; 44(1):78-83. PubMed ID: 27744394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients.
    Alba MA; García-Martínez A; Prieto-González S; Tavera-Bahillo I; Corbera-Bellalta M; Planas-Rigol E; Espígol-Frigolé G; Butjosa M; Hernández-Rodríguez J; Cid MC
    Medicine (Baltimore); 2014 Jul; 93(5):194-201. PubMed ID: 25181312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects.
    Perrineau S; Ghesquière T; Charles P; Paule R; Samson M; Gayraud M; Chauvin A; Terrier B; Guillevin L; Bonnotte B; Mouthon L; Régent A;
    Clin Exp Rheumatol; 2021; 39 Suppl 129(2):155-160. PubMed ID: 33938796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study.
    Hemmig AK; Aschwanden M; Seiler S; Berger CT; Köhn P; Kyburz D; Mensch N; Staub D; Stegert M; Imfeld S; Daikeler T
    RMD Open; 2023 Jan; 9(1):. PubMed ID: 36635003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis.
    Tsalapaki C; Lazarini A; Argyriou E; Dania V; Boki K; Evangelatos G; Iliopoulos A; Pappa M; Sfikakis PP; Tektonidou MG; Georgountzos A; Kaltsonoudis E; Voulgari P; Drosos AA; Theotikos E; Papagoras C; Dimitroulas T; Garyfallos A; Kataxaki E; Vosvotekas G; Boumpas D; Hadziyannis E; Vassilopoulos D
    Rheumatol Int; 2024 Apr; 44(4):603-610. PubMed ID: 38300269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study.
    Kramarič J; Rotar Ž; Tomšič M; Hočevar A
    Front Med (Lausanne); 2022; 9():1069013. PubMed ID: 36438047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.
    Wilson JC; Sarsour K; Collinson N; Tuckwell K; Musselman D; Klearman M; Napalkov P; Jick SS; Stone JH; Meier CR
    Semin Arthritis Rheum; 2017 Jun; 46(6):819-827. PubMed ID: 28040244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of glucocorticoid morbidity in giant cell arteritis.
    Buttgereit F; Matteson EL; Dejaco C; Dasgupta B
    Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii11-ii21. PubMed ID: 29982779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study.
    Tomelleri A; Campochiaro C; Farina N; Mariotti L; Baldissera E; Grayson PC; Matucci-Cerinic M; Dagna L
    Semin Arthritis Rheum; 2023 Apr; 59():152174. PubMed ID: 36774660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis.
    Hachulla E; Boivin V; Pasturel-Michon U; Fauchais AL; Bouroz-Joly J; Perez-Cousin M; Hatron PY; Devulder B
    Clin Exp Rheumatol; 2001; 19(2):171-6. PubMed ID: 11326479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.